Navigation Links
Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
Date:7/21/2010

GREENWOOD VILLAGE, Colo., July 21 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE) today announced the initiation of a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus.

Ampio Pharmaceuticals has completed a formal agreement with St Michael's Hospital, Toronto, Canada as a final step for ethics board approval which is expected in the next few days.  "We are very excited to be commencing this trial and pending the final approval of the ethics board we will commence patient recruitment in the next weeks," stated Don Wingerter, CEO of Ampio Pharmaceuticals. Chief Scientific Officer, Dr. David Bar-Or added, "After accumulating in vitro and animal data, it is gratifying to begin treating patients for this debilitating disease."

Diabetic macular edema and diabetic retinopathy are complications of diabetes mellitus that occur in approximately one third of patients 10 years after the onset of diabetes and are rapidly growing causes of blindness worldwide. There is currently no effective oral medication to treat diabetic macular edema or diabetic retinopathy. Optina™ is a repurposed oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina™ to significantly reduce diabetic macular edema in patients.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near-term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs.

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

Contact: Redwood Consultants, LLC Tel: +1 415-884-0348


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioMEMS Completes CHAMPION Clinical Trial Study
2. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
3. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
4. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
5. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
6. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
7. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
8. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
9. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
10. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... GAITHERSBURG, Md. , Aug. 7, 2017 /PRNewswire/ ... for healthcare member acquisition, retention, and engagement, announced ... Director of Strategy and Product Development, effective as ... strategic consulting and technology implementation strategy for our ... years of experience in consulting and business analytics ...
(Date:8/4/2017)... , Aug. 4, 2017 The search for ... after a physician/patient consult has long been the goal ... a notable focus of the largest meeting of lab ... to healthcare market research firm Kalorama Information.  The firm ... (POCT) offerings or related supplies and software were at ...
(Date:8/2/2017)... AURORA, Ore. , Aug. 2, 2017  Life Flight ... Call Agreement. The agreement improves patient care and operational efficiency ... Springfield , Cottage Grove ... ICU level medical transportation. PeaceHealth and Life Flight Network work ... care available during transport, or when a time sensitive emergency ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press ... mothers. These illustrations show the diversity of the breastfeeding mothers, using bright ... range of sizes. These illustrations are also available on tote bags, notepads, smartphone ...
(Date:8/18/2017)... ... 19, 2017 , ... Mr. Noppadon Pakprot, Deputy Governor for ... Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest “Functional & ... Products and Business at TAT said, “Thailand has long been recognized as a ...
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, ... & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of proactive ... with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... WV (PRWEB) , ... August 18, 2017 , ... ... financial consulting services and asset protection assistance to communities in North-Central West Virginia, ... provide critical services to at-risk boys in the area. , The Chestnut Mountain ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
Breaking Medicine News(10 mins):